Tracking tumor cells in blood for Merkel cell carcinoma patients
Treatments studied
Part of Cancer, Infections clinical trials.
This study looks for cancer cells in your blood before and after surgery (and possibly radiation) to learn more about your cancer and how it responds to treatment. Participation involves giving blood samples, which may help doctors understand your disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have Merkel cell carcinoma (a type of skin cancer) at stage I, II, or III
- You are scheduled to have complete surgical removal of the cancer, or you had complete surgery within the past 6 weeks
- You are not pregnant or breastfeeding
- You are not currently in another research study that has an exclusion period
- You are able to give written informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people with Merkel cell carcinoma, a rare skin cancer, take part in clinical trials. By joining, you help researchers understand how to make trials easier for patients like you.
This trial tests pembrolizumab (an immune therapy) given before surgery to shrink Merkel cell carcinoma and improve outcomes. Participants also have extra tumor biopsies to study biomarkers, which may help explain who benefits most.
This trial tests a combination of two immunotherapy drugs, nivolumab and relatlimab, before surgery for Merkel cell carcinoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial is testing a lab method to see if a specific type of immunotherapy can work against Merkel cell carcinoma. It may help find new treatment options for people with this skin cancer.
This trial looks for signs of cancer DNA in your blood (circulating tumor DNA) to see if it can help track germ cell tumors. It may help doctors find out if your cancer is coming back earlier.
This study measures “circulating tumor markers,” meaning substances from cancer that can show up in blood, to better understand how cancer is doing after treatment. You may join if you recently received cancer care at a participating center and meet basic study and follow-up requirements.
Hear when a new Merkel Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.